Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan

Drug Development and Industrial Pharmacy

Volumn 36, Issue 11, 2010, Pages 1312-1319

  Thornton, Sheila J ^a   Wasan, Kishor M ^a   Piecuch, Anna ^b   Lynd, Larry L D ^a   Wasan, Ellen K ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

Author keywords

Cost; Kala azar; Patient management; Treatment; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PENTOSAM; PM; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

BANGLADESH; BRAZIL; DRUG BIOAVAILABILITY; DRUG COST; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEMOLYSIS; HOSPITALIZATION COST; HUMAN; INCOME; INDIA; INJECTION SITE ULCER; INNER EAR DISEASE; NEPAL; NEPHROTOXICITY; POVERTY; RECOMMENDED DRUG DOSE; REVIEW; SUDAN; VESTIBULAR DISORDER; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIPROTOZOAL AGENTS; COST OF ILLNESS; DISEASE OUTBREAKS; DRUG COSTS; ENDEMIC DISEASES; HOSPITAL COSTS; HUMANS; LEISHMANIASIS, VISCERAL; POVERTY AREAS;

EID: 77956922379     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639041003796648     Document Type: Review

References (41)

1. The World Health Organization. (2000) The leishmaniases and leishmania/HIV co-infections. Geneva: WHO Fact Sheet.
2. Costa CH. (2008). Characterization and speculations on the urbanization of visceral leishmaniasis in Brazil. Cad Saude Publica, 24:2959-2963
3. Hassan MM, Osman OF, El-Rabaa FM, Schallig HD, Elnaiem DE. (2009). Role of the domestic dog as a reservoir host of Leishmania donovani in eastern Sudan. Parasit Vectors, 2:26.
4. Sundar S, Chatterjee M. (2006). Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res, 123:345-352
5. Moore E, OFlaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, et al. (2001). Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ, 79:388-393 (Pubitemid 32488013)
6. Veeken H, Ritmeijer K, Seaman J, Davidson R. (2000). A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health, 5:312-317
7. Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, et al. (2003). Treatment of visceral leishmaniasis in south-eastern Nepal: Decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg, 97:350-354
8. Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, et al. (2008). Drug regimens for visceral leishmaniasis in mediterranean countries. Trop Med Int Health, 13:1272-1276
9. Sundar S, Rai M. (2005). Treatment of visceral leishmaniasis. Expert Opin Pharmacother, 6(16):2821-2829
10. Croft SL, Sundar S, Fairlamb AH. (2006). Drug resistance in leishmaniasis. Clin Microbiol Rev, 19:111-126
11. Davidson RN, den Boer M, Ritmeijer K. (2009). Paromomycin. Trans R Soc Trop Med Hyg, 103:653-660
12. Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. (2009). Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin Infect Dis, 49:914-918
13. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. (2005). Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis, 5:763-774
14. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. (2004). Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations. Clin Infect Dis, 38:377-383
15. Olliaro P, Sundar S. (2009). Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health, 14:88-92.
16. Sundar S, Murray HW. (2005). Availability of miltefosine for the treatment of Kala-azar in India. Bull World Health Organ, 83:394-395
17. Meheus F, Boelaert M, Baltussen R, Sundar S. (2006). Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health, 11:1715-1724
18. Bern C, Chowdhury R. (2006). The epidemiology of visceral leishmaniasis in Bangladesh: Prospects for improved control. Indian J Med Res, 123:275-288
19. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali M, et al. (2003). Visceral leishmaniasis: Consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg, 69:624-628
20. Sharma AD, Bern C, Varghese B, Chowdhury R, Haque R, Ali M, et al. (2006). The economic impact of visceral leishmaniasis on households in Bangladesh. Trop Med Int Health, 11:757-764
21. Luz ZM, Carneiro M, Schall V, Rabello A. (2009). The organization of health services and visceral leishmaniasis: An integrated intervention to improve diagnosis and treatment. Cad Saude Publica, 25:1177-1184
22. Dantas-Torres F, Brandao-Filho SP. (2006). Visceral leishmaniasis in Brazil: Revisiting paradigms of epidemiology and control. Rev Inst Med Trop Sao Paulo, 48:151-156
23. Brasil Ministerio da Saude.(2005). Secretaria de Vigilancia em Saude. Guia de vigilancia epidemiologica/Ministerio da Saude, Secretaria de Vigilancia em Saude. 6th ed. Brasilia: Ministerio da Saude, 816 p. Serie A. Normas e Manuais Tecnicos.
24. Amato, VS, Tuon, FF, Siqueira AM, Nicodemo AC, Neto VA. (2007). Treatment of mucosal leishmaniasis in Latin America: A systematic review. Am J Trop Med Hyg, 77(2):266-274
25. Dietze R, Barros GB, Teixeira L, Harris J, Michelson K, Falqueto A, et al. (1997). Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clin Infect Dis, 25:1240-1242
26. Hotez PJ. (2008). The giant anteater in the room: Brazils neglected tropical diseases problem. PLoS Negl Trop Dis, 2:e177.
27. The World Bank. (2004). Inequality and economic development in Brazil, a World Bank country study. Washington: The International Bank for Reconstruction and Development, XVIII.
28. Schenkel K, Rijal S, Koirala S, Koirala S, Vanlerberghe V, Van der Stuyft P, et al. (2006). Visceral leishmaniasis in southeastern Nepal: A cross-sectional survey on leishmania donovani infection and its risk factors. Trop Med Int Health, 11:1792-1799
29. Adhikari SR, Maskay NM. (2003). The economic burden of Kala-azar in households of the Danusha and Mahottari districts of Nepal. Acta Trop, 88:1-2.
30. Adhikari SR, Maskay NM, Sharma BP. (2009). Paying for hospital-based care of Kala-azar in Nepal: Assessing catastrophic, impoverishment and economic consequences. Health Policy Plan, 24:129-139
31. Rijal S, Koirala S, Van der Stuyft P, Boelaert M. (2006). The economic burden of visceral leishmaniasis for households in Nepal. Trans R Soc Trop Med Hyg, 100(9):838-841
32. Kolaczinski JH, Hope A, Ruiz JA, Rumunu J, Richer M, Seaman J. (2008). Kala-azar epidemiology and control, Southern Sudan. Emerg Infect Dis, 14:664-666
33. Griekspoor A, Sondorp E, Vos T. (1999). Cost-effectiveness analysis of humanitarian relief interventions: Visceral leishmaniasis treatment in the Sudan. Health Policy Plan, 14:70-76
34. Gerstl S, Amsalu R, Ritmeijer K. (2006). Accessibility of diagnostic and treatment centres for visceral leishmaniasis in Gedaref State, northern Sudan. Trop Med Int Health, 11:167-175
35. Alvar J, Yactayo S, Bern C. (2006). Leishmaniasis and poverty. Trends Parasitol, 22:552-557
36. Thakur BB. (2003). Breakthrough in the management of visceral leishmaniasis. J Assoc Physicians India, 51:649-651
37. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, et al. (2007). Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis, 196:591-598 (Pubitemid 47206107)
38. Palumbo E. (2008). Oral miltefosine treatment in children with visceral leishmaniasis: A brief review. Braz J Infect Dis, 12:2-4.
39. Berman JJ. (2008). Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol, 4:1209-1216
40. Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, Werbovetz KA, et al. (2009). Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis, 200:357-360
41. Thornton SJ, Wasan KM. (2009). The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv, 6:271-284